Bio Pharma Dive
MARCH 10, 2021
While Vertex is confident in the therapy, which came via the $1 billion acquisition of Semma Therapeutics, it will still be a few years before the company has a good read on its effects in Type 1 diabetes patients.
World of DTC Marketing
MARCH 10, 2021
SUMMARY: In its simplest form, a creative management platform , or CMP, is a cloud-based software that allows marketing teams to create, distribute, and measure the performance of digital advertising. The advantage is that marketing teams can create online ads without relying on an agency but it requires a digital marketer who fully understands the brand’s target customer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MARCH 10, 2021
The biotech is discussing its findings with U.S. and European regulators in hopes of resuming study of the treatment as well as sales of a related product.
Camargo
MARCH 10, 2021
Technology transfer is a critical step in any drug development program, occurring for various reasons and at different development stages. A sponsor may be looking for a contract development and manufacturing organization (CDMO) for clinical trial manufacturing; to transfer a manufacturing process to a larger, commercial-scale CDMO; or to replace a CDMO that has quality issues.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
MARCH 10, 2021
A low-dose combination of Lilly antibodies for COVID-19 reduced deaths and hospitalizations in a Phase 3 trial, a finding that could boost its use.
Pharma Mirror
MARCH 10, 2021
A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive covid legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in multi-modal disease therapies within five years, mRNA platforms to transform many new non-infectious disease treatment options, and
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
MARCH 10, 2021
Using public relations strategies creates more opportunities for passive candidates to be exposed to your organization – and learn about your open roles.
Scienmag
MARCH 10, 2021
Ten pre-eminent problem solvers honored for scientific, community feats Credit: Randy Montoya ALBUQUERQUE, N.M. — Ten Sandia National Laboratories engineers received Black Engineer of the Year Awards, including Most Promising Scientist, Modern Technology Leaders and Science Spectrum Trailblazers. Honorees include Sandia systems, chemical, computer, electrical, petroleum, manufacturing and mechanical engineers who excel in their respective […].
BioSpace
MARCH 10, 2021
It has been one year since COVID-19 was declared a global pandemic. In that time, more than 118 million people have contracted the virus and 2,622,190 people, including 529,267 in the United States, have died as a result.
Scienmag
MARCH 10, 2021
Credit: Laurence Hartwell Stormier weather will increasingly force fishers to choose between their safety and income, researchers say. Climate change is causing more extreme weather in many locations. Storms will likely increase around the UK in the future, while many fishers in the UK also face economic insecurity. The new study – led by the […].
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
MARCH 10, 2021
Topline results from a trial in Brazil show that treatment with Kintor’s proxalutamide cut mortality risk by 92% and significantly shortened the median length of hospital stay by nine days compared with standard of care in hospitalized patients with COVID-19.
Pharma Times
MARCH 10, 2021
Agreement aims to safeguard rights of people receiving health and social care in England
BioSpace
MARCH 10, 2021
Intellia Therapeutics presented preclinical data of its non-viral genome editing platform at the Keystone eSymposium: Precision Engineering of the Genome, Epigenome and Transcriptome.
Drug Patent Watch
MARCH 10, 2021
Annual Drug Patent Expirations for AXUMIN Axumin is a drug marketed by Blue Earth and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Blue Earth drug AXUMIN appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioSpace
MARCH 10, 2021
According to the Centers for Disease Control and Prevention, more than 35,000 Americans perish each year from antibiotic-resistant infections, and estimates have AMR claiming the lives of as many as 10 million globally by 2050.
Scienmag
MARCH 10, 2021
Using an investigational cell therapy, Medical University of South Carolina pediatricians successfully treated two patients with multisystem inflammatory syndrome in children, a rare but life-threatening complication of COVID-19. Credit: Medical University of South Carolina, Sarah Pack A team of pediatricians at the Medical University of South Carolina (MUSC) was the first in the nation to […].
BioSpace
MARCH 10, 2021
Patients in a Phase II trial have begun receiving Moderna’s vaccine against the SARS-CoV-2 variant first identified in South Africa, the company announced.
Pharma Times
MARCH 10, 2021
Phase I portion of the trial will be conducted at the Manchester clinical unit of MAC Clinical Research
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioSpace
MARCH 10, 2021
The Japanese pharma giant is aiming for double-digit revenue growth of its Growth and Emerging Markets Business Unit (GEM BU) by 2030. Here’s how they plan to do it.
Scienmag
MARCH 10, 2021
Boston University researchers and peers from around the world, after decades of talk, lay out a plan for action Credit: Boston University As the coronavirus pandemic’s grip on the United States stretched from weeks into months, with huge swaths of the American workforce bound to their homes, studies began trickling out revealing that the impact […].
BioSpace
MARCH 10, 2021
“Internal networking” is much the same as regular professional networking, except that the connections or ‘network’ you’re building come from your current employer.
pharmaphorum
MARCH 10, 2021
With so many novel drug candidates for Alzheimer’s disease failing in clinical development, researchers in the US have started using artificial intelligence (AI) to screen already-approved therapies for activity against the neurodegenerative disorder. . A team based at Massachusetts General Hospital and Harvard Medical School has come up with an AI algorithm – called DRIAD (Drug Repurposing In Alzheimer’s Disease) – that it hopes will not only find treatments but also tease out new therapeutic t
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
BioSpace
MARCH 10, 2021
It’s estimated there are more than 17,000 new cases of spinal cord injuries each year, which can cause permanent damage in patients.
Scienmag
MARCH 10, 2021
By enriching soils, they benefit forest recovery and carbon storage Credit: Credit: Sarah Batterman. A new study, published this week in Proceedings of the National Academy of Sciences, reveals that nitrogen-fixing trees play an underrecognized role in recovering tropical forests by enriching nutrient-poor soils with scarce elements such as phosphorus and molybdenum.
pharmaphorum
MARCH 10, 2021
Health Data Research UK’s respiratory hub BREATHE is set to use artificial intelligence (AI) to unlock real-world insights from electronic health records (EHRs) as part of a new partnership. It will apply Savana’s EHRead technology to de-identified EHRs to boost research into COVID-19 and respiratory conditions, work that is also part of the international BigCOVIData study into respiratory disease progression and outcomes.
Scienmag
MARCH 10, 2021
Credit: The Hong Kong University of Science and Technology The research was published on the journal Nature Catalysis on December 14, 2020. A strong bias towards linear and disc-shaped molecules has long been observed in drug molecules. In contrast, spherical molecules have been utilized on far fewer occasions, due to the lack of efficient access […].
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioSpace
MARCH 10, 2021
Genentech reported its rheumatoid arthritis drug Actemra failed to hit its primary endpoint in a COVID-19 trial, while Vir and GlaxoSmithKline’s antibody against COVID-19 demonstrated 85% efficacy.
Scienmag
MARCH 10, 2021
Credit: Jan Potgieter, University of Johannesburg First grade teachers can find out who is on track with math and who is lagging, using an accurate diagnostic test that they can administer in the classroom. After Covid-19 school reopening, or during catch-up sessions in the holidays, this is instrument can also be useful, especially in large, […].
pharmaphorum
MARCH 10, 2021
A laboratory study suggests Pfizer and BioNTech’s COVID-19 vaccine Comirnaty could be effective against a Brazilian variant of the SARS-CoV-2 virus – known as P.1 – that is worrying health officials around the world. . The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 mutations, as well as variants from the UK and South Africa.
Scienmag
MARCH 10, 2021
Credit: Novak et al, 2021, PLOS ONE (CC-BY 4.0, [link] Genetic analysis provides clarity and also prompts further questions around an ancient massacre in Poto?ani, Croatia, in a study published March 10, 2021 in the open-access journal PLOS ONE by Mario Novak from the Institute for Anthropological Research, Croatia, Ron Pinhasi from the University of […].
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
323 
Let's personalize your content